A Phase 4 interventional study of Insulin glargine, 300 units per milliliter (U/mL) and Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra) in Type 1 Diabetes Mellitus, sponsored by Sanofi. Terminated at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-07.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 64th largest by enrollment, is one of 4 that started in 2017, is one of 24 in phase 4, and was the 52nd registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 73 across the 66 interventional studies. Of the 63 that completed or were terminated, 24 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 66 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
67 studies in Diabetes Mellitus, Type 1 by Sanofi: 6 open now, 10 under way, 1 of them phase 3. Of 56 finished, 13 (23%) have results posted.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is the 56th largest by enrollment of the 60 interventional ones that give a count, is one of 6 that started in 2017, is one of 14 in phase 4, and was the 45th registered.
Sanofi’s Diabetes Mellitus, Type 1 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 67 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the effect of virtual approach via novel technologies versus traditional study conduct on glycemic control in terms of glycated hemoglobin (HbA1c).
Secondary Objective:
To evaluate the appropriate utilization of virtual approach via novel technologies during the study and to assess the effect of the virtual versus traditional study conduct on multiple outcomes in terms of study methodology and diabetes management.
The study had a maximum study duration of 29 weeks, which consisted of a 3-week screening period (including a possible 1-week delay in first investigational medicinal product [IMP] administration after randomization in virtual group due to shipment of IMP and the virtual devices), a 24-week treatment period, and 1-week post-treatment safety follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants included in this virtual trial approach group did not visit the study sites during the study course. All study assessments, including vital signs, weight, laboratory variables, etc., were completed via the Bluetooth devices that instantly transfer the digital data.
Drug: Insulin glargine, 300 units per milliliter (U/mL) · Drug: Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
Participants included in this traditional trial approach group visited the study site, followed the study visit schedules for all study assessments that was performed either in-person or phone visits.
Drug: Insulin glargine, 300 units per milliliter (U/mL) · Drug: Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
Drug page: Insulin Glargine
Self-administered subcutaneous injection using prefilled pen once daily for 24 weeks. Dose titration to achieve fasting self-monitoring of plasma glucose (SMPG) level between 80 and 130 milligram per deciliter (mg/dL).
Also known as: Toujeo ®
Subcutaneous injection.
Change From Baseline in Glycated Hemoglobin A1c (HbA1c) to Week 24
Change in HbA1c was calculated by subtracting baseline value from Week 24 value.
Time frame: Baseline, Week 24
Change From Baseline in Glycated Hemoglobin A1c to Week 16
Change in HbA1c was calculated by subtracting baseline value from Week 16 value.
Time frame: Baseline, Week 16
Change From Baseline in Fasting Plasma Glucose (FPG) to Week 16 and Week 24
Change in FPG was calculated by subtracting baseline value from Week 16 value (for change at Week 16) and Week 24 (for change at Week 24) value.
Time frame: Baseline, Week 16, Week 24
Participant Satisfaction With Trial Experience: Was It Worth It (WIWI) Questionnaire Response at Week 24
Participant satisfaction with trial experience was measured using the WIWI questionnaire. The WIWI had 5 questions, 3 questions with level categorical response (Yes, No, and Unsure) scale, 1 question with 3 possible answers as: Better than I expected/The same as I expected/Worse than I expected, and 1 question with 3 possible answers: It improved/Stayed the same/Become worse.
Time frame: At Week 24
Change From Baseline in Work Productivity and Impairment-Study Participation (WPAI-SP) Scores to Week 24
Effect of trial on a participants' ability to work and perform regular activities were measured using WPAI-SP. WPAI-SP had 6 items scored separately, where higher score indicated greater impairment and less productivity.
Time frame: Baseline, Week 24
Change From Baseline in Overall Study Experience-Participation (OSEP) Part-1 Questionnaire Score to Week 24
Participant burden with trial participation was measured using the OSEP Questionnaire, administered electronically. OSEP Part-1 contained 4 items to examine perceptions of study participation. Each item was measured on an 11 point scale ranged from 0 (completely disagree) to 10 (completely agree), where higher score indicated higher perception of diabetes control.
Time frame: Baseline, Week 24
Change From Baseline in Overall Study Experience-Participation Part-2 Questionnaire Score to Week 24
Participant burden with trial participation was measured using the OSEP Questionnaire, administered electronically. OSEP Part-2 contained 9 items to examine perceptions of study participation. Each item was measured on an 11 point scale ranged from 0 (completely disagree) to 10 (completely agree), where higher score indicated higher burden with trial participation.
Time frame: Baseline, Week 24
Resource Use Questionnaire (RUQ) Scores
Healthcare resource use was measured using the RUQ which asked participants to report the resources used (time and expenses) during the previous 4 weeks in terms of visits to healthcare professionals.
Time frame: During 24 weeks treatment period
Change From Baseline in Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) to Week 24
The DTSQs was a validated questionnaire to assess participant's satisfaction with their diabetes treatment. It consisted of 8 items that were answered on a Likert scale from 0 (no satisfaction) to 6 (high satisfaction with treatment). Total treatment satisfaction score was the sum of items 1, 4-8 scores and ranged from 0 (no satisfaction) to 36 (high satisfaction with treatment).
Time frame: Baseline, Week 24
Change From Baseline in Diabetes Treatment Satisfaction Questionnaire Change (DTSQc) Score to Week 24
DTSQc measured the relative change in treatment satisfaction from previous therapy. It consists of 8 items that were answered on a 6 point scale ranges from 3 (much less satisfied) to -3 (much more satisfied). Total treatment satisfaction score was the sum of items 1, 4-8 scores and ranged from -18 (much less satisfied) to +18 (much more satisfied), higher score indicated more satisfaction.
Time frame: Baseline, Week 24
Hypoglycemia Fear Survey-II (HFS-II) Scores
Fear of hypoglycemia was measured with HFS-II at Week 24. The HFS-II comprises 33 items: 15 items explore behaviors that participants were engaged in to avoid low blood sugar and its negative consequences and 18 items related to concern/worry that participants had about their hypoglycemia. Responses to each item were made on a 5-point Likert scale ranges from 0 equal (=) "Never" to 4 = "Always". Total HFS mean score was determined by computing the mean of all 33 items and the score ranged from 0 to 4, where higher score indicated more fear/worry.
Time frame: At Week 24
Diabetes Distress Scale (DDS) Scores
Diabetes-related distress was measured using DDS. The DDS contained 17 items related to potential problem areas that people with diabetes may experience. Participants were asked to consider the degree to which each of the items might have distressed or bothered them during the past month, and respond for each item on a 7 point scale ranges from 1 (not a problem) to 6 (a very serious problem), higher score indicated more diabetes related distress.
Time frame: Week 0, Week 24
Change From Baseline in 7-Point Self-Monitoring of Plasma Glucose (SMPG) Profiles at Week 16 and Week 24 Per Time Point
7-point SMPG profiles were measured at the following 7 points at each visit (Baseline, Week 16, and Week 24): before breakfast, 2 hours after breakfast, before lunch, 2 hours after lunch, before dinner, 2 hours after dinner, and bedtime. For each time point, the value at each visit was calculated as the average of values obtained for the same time point across profiles performed in the week before the visit.
Time frame: Baseline, Week 16, Week 24
Average Daily Insulin Doses
Average daily insulin doses included basal insulin doses, mealtime insulin doses, and total insulin doses.
Time frame: During 24 weeks treatment period
Overall Study Experience-Sites (OSES) Questionnaire Part-1: Hours Spent by Investigator
An OSES questionnaire was completed by Site Investigator and had 2 parts. The OSES Part-1 contained quantitative 1 item (question) to examine resource requirements which was: Approximately how much time did you spend with this participant (in person or via phone) during this scheduled visit/communication? (hours)
Time frame: During 24 weeks treatment period
Overall Study Experience-Sites Questionnaire Part-2 Scores for Site-Perceived Participant Relationship and Satisfaction at Week 24
An OSES questionnaire was completed by site investigator and had two parts. OSES Part-2 contains 2 items to examine investigator-participant relationship and satisfaction with care. Both items were assessed on a scale of 0 \[completely disagree\] to 10 \[completely agree\]), where highest score indicated a good relationship and satisfaction with care.
Time frame: At Week 24
Number of Participants With At Least One Hypoglycemic Events (Any, Severe Documented Symptomatic, Probable Symptomatic, Asymptomatic, Pseudo-hypoglycemia: Any Time of the Day) During 24 Week Treatment Period
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycemia: an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<=3.9 mmol/L (70 mg/dL) or \<3.0 mmol/L (54 mg/dL). Asymptomatic hypoglycemia: an event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration \<=3.9 mmol/L (70 mg/dL) or \<3.0 mmol/L (54 mg/dL). Probable symptomatic hypoglycemia: an event during which symptoms of hypoglycemia were not accompanied by plasma glucose determination but was presumably caused by a plasma glucose concentration. Pseudo-hypoglycemia: an event with any of the typical symptoms of hypoglycaemia with plasma glucose concentration \>3.9 mmol/L (70 mg/dL).
Time frame: During 24 weeks treatment period
Participants were enrolled in the study at 6 sites in Canada and United States between 19 September 2017 and 02 October 2018.
| Milestone | Virtual | Traditional |
|---|---|---|
| Started | 8 | 7 |
| Safety population | 8 | 6 |
| Completed | 5 | 4 |
| Not completed | 3 | 3 |
| Withdrew: Poor compliance to protocol | 0 | 2 |
| Withdrew: Study terminated by sponsor | 2 | 1 |
| Withdrew: Other than specified above | 1 | 0 |
Change in HbA1c was calculated by subtracting baseline value from Week 24 value.
| percentage of HbA1c | Virtual | Traditional |
|---|---|---|
| Change From Baseline in Glycated Hemoglobin A1c (HbA1c) to Week 24 | 0.10 ± 0.76 | 0.33 ± 0.57 |
Change in HbA1c was calculated by subtracting baseline value from Week 16 value.
| percentage of HbA1c | Virtual | Traditional |
|---|---|---|
| Change From Baseline in Glycated Hemoglobin A1c to Week 16 | 0.23 ± 0.52 | 0.45 ± 0.13 |
Change in FPG was calculated by subtracting baseline value from Week 16 value (for change at Week 16) and Week 24 (for change at Week 24) value.
| millimole per liter (mmol/L) | Virtual | Traditional |
|---|---|---|
| Week 16 | -0.660 ± 2.387 | -0.200 ± 4.555 |
| Week 24 | -3.625 ± 3.406 | 2.900 ± 1.758 |
Participant satisfaction with trial experience was measured using the WIWI questionnaire. The WIWI had 5 questions, 3 questions with level categorical response (Yes, No, and Unsure) scale, 1 question with 3 possible answers as: Better than I expected/The same as I expected/Worse than I expected, and 1 question with 3 possible answers: It improved/Stayed the same/Become worse.
No measurements were reported for this outcome.
Effect of trial on a participants' ability to work and perform regular activities were measured using WPAI-SP. WPAI-SP had 6 items scored separately, where higher score indicated greater impairment and less productivity.
No measurements were reported for this outcome.
Participant burden with trial participation was measured using the OSEP Questionnaire, administered electronically. OSEP Part-1 contained 4 items to examine perceptions of study participation. Each item was measured on an 11 point scale ranged from 0 (completely disagree) to 10 (completely agree), where higher score indicated higher perception of diabetes control.
No measurements were reported for this outcome.
Participant burden with trial participation was measured using the OSEP Questionnaire, administered electronically. OSEP Part-2 contained 9 items to examine perceptions of study participation. Each item was measured on an 11 point scale ranged from 0 (completely disagree) to 10 (completely agree), where higher score indicated higher burden with trial participation.
No measurements were reported for this outcome.
Healthcare resource use was measured using the RUQ which asked participants to report the resources used (time and expenses) during the previous 4 weeks in terms of visits to healthcare professionals.
No measurements were reported for this outcome.
The DTSQs was a validated questionnaire to assess participant's satisfaction with their diabetes treatment. It consisted of 8 items that were answered on a Likert scale from 0 (no satisfaction) to 6 (high satisfaction with treatment). Total treatment satisfaction score was the sum of items 1, 4-8 scores and ranged from 0 (no satisfaction) to 36 (high satisfaction with treatment).
No measurements were reported for this outcome.
DTSQc measured the relative change in treatment satisfaction from previous therapy. It consists of 8 items that were answered on a 6 point scale ranges from 3 (much less satisfied) to -3 (much more satisfied). Total treatment satisfaction score was the sum of items 1, 4-8 scores and ranged from -18 (much less satisfied) to +18 (much more satisfied), higher score indicated more satisfaction.
No measurements were reported for this outcome.
Fear of hypoglycemia was measured with HFS-II at Week 24. The HFS-II comprises 33 items: 15 items explore behaviors that participants were engaged in to avoid low blood sugar and its negative consequences and 18 items related to concern/worry that participants had about their hypoglycemia. Responses to each item were made on a 5-point Likert scale ranges from 0 equal (=) "Never" to 4 = "Always". Total HFS mean score was determined by computing the mean of all 33 items and the score ranged from 0 to 4, where higher score indicated more fear/worry.
No measurements were reported for this outcome.
Diabetes-related distress was measured using DDS. The DDS contained 17 items related to potential problem areas that people with diabetes may experience. Participants were asked to consider the degree to which each of the items might have distressed or bothered them during the past month, and respond for each item on a 7 point scale ranges from 1 (not a problem) to 6 (a very serious problem), higher score indicated more diabetes related distress.
No measurements were reported for this outcome.
7-point SMPG profiles were measured at the following 7 points at each visit (Baseline, Week 16, and Week 24): before breakfast, 2 hours after breakfast, before lunch, 2 hours after lunch, before dinner, 2 hours after dinner, and bedtime. For each time point, the value at each visit was calculated as the average of values obtained for the same time point across profiles performed in the week before the visit.
No measurements were reported for this outcome.
Average daily insulin doses included basal insulin doses, mealtime insulin doses, and total insulin doses.
No measurements were reported for this outcome.
An OSES questionnaire was completed by Site Investigator and had 2 parts. The OSES Part-1 contained quantitative 1 item (question) to examine resource requirements which was: Approximately how much time did you spend with this participant (in person or via phone) during this scheduled visit/communication? (hours)
No measurements were reported for this outcome.
An OSES questionnaire was completed by site investigator and had two parts. OSES Part-2 contains 2 items to examine investigator-participant relationship and satisfaction with care. Both items were assessed on a scale of 0 \[completely disagree\] to 10 \[completely agree\]), where highest score indicated a good relationship and satisfaction with care.
No measurements were reported for this outcome.
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycemia: an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<=3.9 mmol/L (70 mg/dL) or \<3.0 mmol/L (54 mg/dL). Asymptomatic hypoglycemia: an event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration \<=3.9 mmol/L (70 mg/dL) or \<3.0 mmol/L (54 mg/dL). Probable symptomatic hypoglycemia: an event during which symptoms of hypoglycemia were not accompanied by plasma glucose determination but was presumably caused by a plasma glucose concentration. Pseudo-hypoglycemia: an event with any of the typical symptoms of hypoglycaemia with plasma glucose concentration \>3.9 mmol/L (70 mg/dL).
| Participants | Virtual | Traditional |
|---|---|---|
| Any hypoglycemia | 7 | 3 |
| Severe hypoglycemia | 0 | 0 |
| Documented symptomatic hypoglycemia: <=3.9 mmol/L | 6 | 3 |
| Documented symptomatic hypoglycemia: <3.0 mmol/L | 4 | 3 |
| Probable symptomatic hypoglycemia | 0 | 0 |
| Asymptomatic hypoglycemia <=3.9 mmol/L | 4 | 3 |
| Asymptomatic hypoglycemia <3.0 mmol/L | 1 | 1 |
| Pseudo-hypoglycemia >3.9 mmol/L | 1 | 0 |
Collected over All Adverse Events (AEs) were collected from time of first dose of study drug up to 25 weeks regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Virtual | 0/8 (0%) | 1/8 (12.5%) | 2/8 (25%) |
| Traditional | 0/6 (0%) | 1/6 (16.7%) | 4/6 (66.7%) |
| Event | Virtual | Traditional |
|---|---|---|
| Loss Of ConsciousnessNervous system disorders | 0/8 | 1/6 |
| Obstructive PancreatitisGastrointestinal disorders | 1/8 | 0/6 |
| Cholecystitis AcuteHepatobiliary disorders | 1/8 | 0/6 |
| Escherichia BacteraemiaInfections and infestations | 1/8 | 0/6 |
| Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders | 1/8 | 0/6 |
| Event | Virtual | Traditional |
|---|---|---|
| NasopharyngitisInfections and infestations | 0/8 | 2/6 |
| DiarrhoeaGastrointestinal disorders | 0/8 | 1/6 |
| Oedema PeripheralGeneral disorders | 0/8 | 1/6 |
| Gastroenteritis ViralInfections and infestations | 0/8 | 1/6 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/8 | 1/6 |
| Alcohol PoisoningInjury, poisoning and procedural complications | 0/8 | 1/6 |
| Head InjuryInjury, poisoning and procedural complications | 0/8 | 1/6 |
| Intervertebral Disc DegenerationMusculoskeletal and connective tissue disorders | 0/8 | 1/6 |
| Vertebral OsteophyteMusculoskeletal and connective tissue disorders | 0/8 | 1/6 |
| CholelithiasisHepatobiliary disorders | 1/8 | 0/6 |
Analysis was performed on randomized population which included any participant who was allocated to a study conduct approach group regardless of whether the study conduct approach group was followed.
| Age, Continuous(years) | Virtual | Traditional | Total |
|---|---|---|---|
| Mean | 53.1 ± 5.6 | 45.6 ± 14.3 | 49.6 ± 10.9 |
| Sex: Female, Male(Participants) | Virtual | Traditional | Total |
|---|---|---|---|
| Female | 2 | 0 | 2 |
| Male | 6 | 7 | 13 |
| Race (NIH/OMB)(Participants) | Virtual | Traditional | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 8 | 7 | 15 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Body mass index (BMI)(kilogram per meter square (kg/m^2)) | Virtual | Traditional | Total |
|---|---|---|---|
| Mean | 38.2 ± 18.4 | 30.9 ± 4.1 | 34.8 ± 13.8 |
| Duration of Type 1 Diabetes(years) | Virtual | Traditional | Total |
|---|---|---|---|
| Mean | 32.4 ± 11.5 | 19.3 ± 12.7 | 26.3 ± 13.4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Sep 2017 to primary completion in Nov 2018, 14 months.
Results were first posted in Jan 2020, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine